Leukemia stem cells (LSCs) have critical functions in acute leukemia (AL) pathogenesis, participating in its initiation and relapse. Thus, identifying new molecules to eradicate LSCs represents a high priority for AL management. This work identified E35, a novel Emodin derivative, which strongly inhibited growth and enhanced apoptosis of AL stem cell lines, and primary stem and progenitor cells from AL cases, while sparing normal hematopoietic cells. Furthermore, functional assays in cultured cells and animals suggested that E35 preferentially ablated primitive leukemia cell populations without impairing their normal counterparts. Moreover, molecular studies showed that E35 remarkably downregulated drug-resistant gene and dramatically inhibited the Akt/ mammalian target of rapamycin signaling pathway. Notably, the in vivo anti-LSC activity of E35 was further confirmed in murine xenotransplantation models. Collectively, these findings indicate E35 constitutes a novel therapeutic candidate for AL, potentially targeting leukemia stem and progenitor cells. K E Y W O R D S acute leukemia, Akt/mTOR, apoptosis, E35, leukemia stem/progenitor cells, xenograft model ---
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1 | INTRODUCTION Acute leukemia (AL) represents a clonal hematopoietic stem cell (HSC) dysregulation marked by arrested differentiation, unsuitable growth of immature progenitor cells. Persistence of leukemia stem cells (LSCs) constitutes an important factor that contributes to both initiation and relapse in patients with AL. Meanwhile, LSCs typically are quiescent and not susceptible to most conventional chemotherapy regimens. In addition, currently available regimens might not efficiently distinguish normal from malignant cells (Akbarzadeh et al., 2019; Bonnet & Dick, 1997; Guan, Gerhard, & Hogge, 2003; Guzman et al., 2005; Lapidot et al., 1994; van Rhenen et al., 2005) . Thus, identifying novel molecules that could specifically target LSCs represents a high priority for leukemia therapy.
Emodin, a plant-derived anthraquinone, has recently attracted increasing attention because of its overt pharmacological features in cancer therapy (Fu et al., 2012; Liu et al., 2016; Subramaniam et al., 2013) . Brown, Bellon, and Nicot (2007) and our previous studies demonstrated the promising anti-leukemic activities of Emodin in different types of hematological malignancies (Chen et al., 2014; Chen, Mei et al., 2018) . We showed that Emodin can enhance all-trans retinoic acid (ATRA)-associated differentiation and induce apoptotic death in acute myeloid leukemia (AML) cells (Chen et al., 2014) . In addition, our team found that Emodin may significantly increase the chemosensitivity of resistant AML cells to cytarabine (Ara-C; . Our recent study further demonstrated that TP53 and PI3K are the targets by which Emodin may function in diffuse large B cell lymphoma (Chen, Mei et al., 2018) . However, Emodin is poorly soluble, which limits its potential application in clinic.
For identifying novel agents possessing enhanced drug-like features, we recently designed, synthesized, and biologically evaluated a series of Emodin derivatives with quaternary ammonium salt (China Patent ZL201110045332.8, ZL201510406814.X, ZL201510868080.7) (Hu et al., 2019; Li et al., 2015; Shao et al., 2012; Wang et al., 2012) .
Among these compounds, E35 (C 34 H 50 BrNO 5 ·H 2 O, MW: 631.29), which was obtained by introducing a long quaternary ammonium salt containing a long carbon chain to Emodin, exhibited potent antileukemia effects with low half maximal inhibitory concentration (IC50) values and markedly enhanced aqueous solubility. The positive charge of quaternary ammonium salt makes it easy for E35 to enter the mitochondria of cancer cells preferentially. Meanwhile, the long carbon chain renders E35 lipophilic and allows it to pass through the mitochondrial membrane easily (Hu et al., 2019; Li et al., 2015) . E35 was interestingly found to have significant inhibitory effects on chronic myeloid leukemia (CML) 32Dp210-T315I cells harboring T315I mutation in our previous report . It is well-accepted that the T315I gatekeeper mutation promotes resistance to both imatinib and second-generation tyrosine kinase inhibitors, such as nilotinib and dasatinib in patients with CML (O'Hare et al., 2005; Tamai et al., 2018) .
According to its properties, E35 attracts increasing attention as a potential therapeutic for leukemia. Hence, we sought to further determine the biological significance of E35 in AL cells, especially in AL stem/progenitor cells. The present study demonstrated that LSCs are extremely sensitive to E35 treatment and undergo extensive apoptosis. Importantly, E35 efficiently suppressed human AL stem and progenitor cells, with no overt toxic effects on normal hematopoietic cells in culture or mice. These findings suggest E35 represents a potential new drug for treating hematologic cancers, particularly targeting AL stem/progenitor cells.
| MATERIALS AND METHODS

| Cell culture
Human multidrug resistant HL-60/ADR cells and HL-60 cells were from the Institute of Hematology, Chinese Academy of Medical Sciences. Highly malignant leukemia HL-60/H3 cells were obtained from HL-60 xenografts in the nude mouse model. ATRA-resistant MR2 and NB4 cells were provided by Shanghai Institute of Hematology, Shanghai Ruijing Hospital, China. U937, CEM, Jurkat, Molt-4, and CA46 cells were provided by CCTCC (China Center for Type Culture Collection, China). Cell culture followed the procedures described in our previous study (Chen et al., 2014) . Human leukemic stem-like KG1a cells (>95% CD34 + CD38 − , American Type Culture Collection, ATCC) were maintained in Iscove's Modified Dulbecco's medium containing 10% fetal bovine serum (Gibco-BRL) at 37℃ in a humid incubator containing 5% CO 2 . CD34 + cells enriched from HL-60/ADR cells were termed HARs. E35 stock solution was prepared as reported in our previous study .
| Primary cell isolation
Peripheral blood was collected from 33 primary patients with AL. The specimens contained ≥70% blasts before any manipulation. All patients had AL, as described by standard French-American-British and WHO criteria. Cases and healthy volunteers provided informed consent, and the study had approval from the institutional review board of Fujian Medical University Union Hospital, and was carried out according to the Declaration of Helsinki. Normal control samples were from six healthy HSC donors upon granulocyte colonystimulating factor mobilization. Peripheral blood mononuclear cells (PBMCs) were purified by Ficoll-Paque density-gradient separation.
The percentages of CD34 + cells in samples ranged from 4.0% to 97.6%. CD34 + cells were further selected from PBMCs with CD34 MicroBead Kit (MiltenyiBiotec). CD34 + cell populations with a purity >90% were used in all experiments. Primary cells were incubated with medium without serum supplementation for 1 hr before E35 treatment (Lansdorp & Dragowska, 1992 ).
| Drug susceptibility assessment
Drug susceptibility was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as previously reported by our team (Chen et al., 2014; . Cells seeded in 96-well plates (Costar) for 0-72 hr were incubated with or without E35 at 37℃ in a humidified incubator containing 5% CO 2 . MTT (5 mg/ml, Sigma) in phosphate-buffered saline was supplemented (10 µl/well), followed by 4 hr of incubation. After supernatant removal, dimethyl sulfoxide was employed to dissolve formazan crystals. All experiments were carried out in triplicate. Absorbance was assessed on a spectrophotometer (STAT FAX-2100) at 492/ 630 nm. Cell survival and inhibitory rates were derived as (optical density [OD] treated /OD control ) × 100% and (1−OD treated /OD control ) × 100%, respectively. IC50 was determined by the Logit method.
| Methylcellulose colony-forming assay
A total of 500 CD34 + cells were seeded in 6-well plates with 1 ml per well of complete methylcellulose medium supplemented with recombinant cytokines (MethoCult H4435; Stem Cell Technologies), and treated or not with E35. The colonies (>40 cells) were counted after 14 days of culture. The average percentages of colony-forming units (CFUs) were obtained based on nontreated cells.
| Nonobese diabetic/severe combined immunodeficiency mouse repopulating cell assay
Nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice (6-8 weeks; Shanghai Slac Laboratory Animal Co., Ltd.) were intravenously administered 25 mg·kg −1 ·day −1 busulfan (DSM Pharmaceuticals, Inc.) on days −2 and −1 before transplantation. Primary AL cells and healthy donor cells were incubated with 16 µM E35 or not for 18 hr, and then transplanted into busulfan preconditioned NOD/SCID mice (1 × 10 7 cells/mouse). After 8 weeks, bone marrow cells were collected and incubated with antihuman CD45 antibodies (BD Biosciences). Human cells in various recipients were detected flow-cytometrically.
| Flow cytometric assessment of apoptosis and cell cycle distribution
HARs and KG1a cells were harvested after exposure to E35 for 24 hr, and underwent staining with CD34-APC and CD38-FITC antibodies detecting surface molecules (Becton Dickinson). Apoptotic rates were assessed using an Annexin V-phycoerythrin (PE)/7-aminoactinomycin (7-AAD) staining kit (Becton Dickinson) as directed by the manufacturer. Flow cytometry was then employed for analysis on a BD Verse (Becton Dickinson). To analyze the cell cycle distribution, cells underwent treatment with E35 for 48 hr. Then, single cell suspensions underwent fixation with 70% chilled ethyl alcohol for 2 hr and incubated with RNase A at 37℃ for 30 min, and incubated with propidium iodide (KeyGEN BioTECH) at 4℃ for 30 min. Flow cytometric assessment was carried out to obtain cell amounts in various phages (G0/G1, S, and G2/M), respectively.
| Quantitative real-time polymerase chain reaction
HARs and KG1a cells were administered E35 for 24 hr. Total RNA was obtained with RNeasy Mini Kit (Qiagen) according to the kit's specifications. RNA amounts and purity were assessed by UV spectrophotometry (Nanodrop). Reverse transcription was performed with OligodT primers and reverse transcriptase (Promega). Quantitative real-time polymerase chain reaction (qRT-PCR) was performed with SYBR Green on an ABI prism 7700 sequence detection system (Applied Biosystems) using Real Master Mix kit (Tiangen, China). Table 1 lists primer sequences for GAPDH, MDR1, MRP1, TopⅡβ, GSTπ, and BCL-2 detection by qRT-PCR. Relative messenger RNA (mRNA) amounts were determined by the −ΔΔ 2 Ct method, and normalized to GAPDH expression (Lin et al., 2013; Wang et al., 2015) .
| Western blot analysis
HARs and KG1a cells were administered increasing E35 amounts for 24 hr. Immunoblot was carried out upon cell treatment following reported protocols (J. Hu et al., 2011) . Antihuman
Procaspase-9, Procaspase-3, p-Akt (Thr308), Akt, p-4E-BP1 (Thr70), 4E-BP1 (53H11), p-p70S6K (Thr389), and p70S6K primary antibodies were provided by Cell Signaling Technology;
anti-MRP1 primary antibodies from Boster Biological Technology (China), and anti-MDR1, GSTπ, TopⅡβ (C-12), BCL-2, and β-actin primary antibodies provided by Santa Cruz Biotechnology were also employed.
Abbreviation: qRT-PCR, quantitative real-time polymerase chain reaction. 
| Statistical analysis
Data are mean ± standard deviation, and were evaluated by t test.
GraphPad Prism 6.0 was employed for statistical analysis. Significance level was set at p < .05. The IC50 values of E35 in the 10 cell lines were between 1.48 ± 0.31 µM and 3.67 ± 0.69 µM, that is, 6.07-and 25.47-fold lower than those of Emodin as previously reported by our team (Chen et al., 2014; ; Table 2 ).
| E35 preferentially targets primitive leukemia cells and spares non-diseased hematopoietic cells
HARs and KG1a cells (both bearing more than 95% CD34 + CD38 − immunophenotype, Figure 1a were administered E35 at different levels. All of the primary cells from AL patients with different subtypes were affected by E35, with IC50 values of 13.86 ± 9.35 µM ( Figure 1d ). Figure 1e shows that primary AL cells were dose-dependently inhibited by E35. At E35 concentrations of 8, 16, and 32 µM, mean viability rates in total cell populations were 63.60 ± 3.87% (n = 33), 41.68 ± 3.90% (n = 33) and 16.63 ± 3.09% (n = 21), respectively. Next, cell death in CD34 + primitive AL cells was assessed. Cells administered E35 at 8, 16, and 32 µM showed 53.12 ± 6.32% (n = 20), 29.68 ± 4.18% (n = 17), and 15.98 ± 6.71% (n = 7) mean viability rates, respectively. To verify E35 specificity for cancer cells, normal hematopoietic cells were examined. As shown in Figure 1f , both total and CD34 + cells from normal samples showed no overt viability reduction upon treatment with 8 and 16 µM E35 (89.86 ± 3.05% vs. 79.43 ± 3.73%, respectively, p = 0.06, n = 6 for total cells; and 103.8 ± 5.13% vs. 94.09 ± 4.79%, respectively, p = 0.195, n = 6 for CD34 + cells). When administered E35 as high as 32 µM, the results showed that viability in total and CD34 + healthy cells was 64.04 ± 3.81% (n = 6) and 75.33 ± 4.96% (n = 6), respectively, that is, 3.9-fold and 4.7-fold higher than those observed in total and in CD34 + AL cells administered 32 µM E35.
| E35 decreases leukemic but not normal stem and progenitor cell activity
The in vitro colony formation assay was employed to assess whether E35 altered colony formation in primitive cells. Figure 2a, (Chen et al., 2014; .
exposed to increasing doses (8 and 16 µM) of E35. For comparison, we further treated CD34 + cells from healthy donors (n = 6) and AL cases (n = 7) with 16 µM E35 for 14 days and assessed CFUs. The results revealed that CFUs from normal donors were slightly decreased by about 20%; however, CFUs from patients with AL were strongly inhibited by more than 90% upon E35 treatment (Figure 2a,c) .
3.4 | E35 reduces NOD/SCID repopulating ability in AL cells but not normal cells NOD/SCID mouse xenograft assays were performed to assess whether E35 targets functionally defined leukemia progenitor/stem cells. Primary AL and normal cells after an 18-hr treatment with E35
were administered to immunodeficient NOD/SCID mice. Bone marrow cells were collected and examined for human-derived CD45 cells in recipients at 8 weeks after transplantation. Figure 3a shows that E35 treatment markedly reduced human leukemic cell engraftment in NOD/SCID mice. The engraftment levels of seven independent AL specimens in the recipients were decreased by 85% compared with the untreated group (p = .005, n = 7). In contrast, hCD45 cell assessment in animals treated versus untreated healthy cells showed no statistically significant difference (Figure 3b ; p = .742, n = 4), indicating that E35 specifically targets AL stem/ progenitor cells with no effect on the engraftment potential of normal primitive cells. with E35 significantly increased the cell amounts in the G0/G1 phase (78.79 ± 2.18% vs. 53.92% ± 2.27%, p = .0014 for HARs; and 77.24 ± 1.35% vs. 59.91% ± 1.03%, p = .0005 for KG1a cells). The S phase cell rates were similar in both groups of KG1a cells (15.81 ± 3.60% vs. 23.09 ± 0.66%; p = .117), while there was a dramatic reduction of cell proportion in the S phase in HARs after treatment with E35 (14.64 ± 1.84% vs. 34.68 ± 1.86%; p = .0016). The proportion of G2/M phase cells upon E35 administration was markedly reduced in comparison with the control value (6.58 ± 0.40% vs. 11.40% ± 0.91%, p = .0083 for HARs; and 7.21 ± 2.37% vs. 17.25 ± 0.60%, p = .015 for KG1a cells; Figure 5a,b ).
| E35 downregulates drug resistance genes and inhibits the Akt/mammalian target of rapamycin signaling pathway
To evaluate the molecular consequences of E35 treatment in primitive leukemia cells, we examined the expression changes of drug-resistant genes by qRT-PCR and immunoblot, respectively. As depicted in Figure 6a ). Wright-Giemsa-stained sections showed elevated immature blast cell infiltration in the bone marrow from saline control mice. In contrast, bone marrow samples from E35-conditioned mice were dominated by more mature myeloid cells at various differentiation levels ( Figure 6b ). Flow cytometric analysis was also performed to track human KG1a-R cells in the bone marrow from individual mice. As shown in Figure 6c , the percentages of CD34 + CD38 − KG1a-R cells in recipients were markedly reduced following E35 treatment in comparison with control values (p < .0001). Of note, all treated animals appeared healthy;
none of them appeared to succumb to therapeutic toxicity, and all survived to the end of observation. In contrast, one mouse in the saline control group died due to rapid disease progression (data not shown).
Hence, the in vivo study further confirmed the potential of E35 for the eradication of leukemic stem/progenitor cells.
| DISCUSSION
AL arises from immature cells in the bone marrow. It represents a severe and common hematologic malignancy. Because LSCs play a critical role in AL initiation, multidrug resistance and recurrence of leukemia (Bonnet & Dick, 1997; Lapidot et al., 1994; Ratajczak, Bujko, Mack, Kucia, & Ratajczak, 2018; van Rhenen et al., 2007) , selectively targeting LSCs has been identified as a promising strategy for leukemia treatment (Baquero et al., 2018; Ding et al., 2016; Guzman et al., 2014; Liu et al., 2013; Tremblay et al., 2018) . Here, we provide the first in vitro and in vivo evidence that E35, a novel Emodin derivative, preferentially eradicates AL stem and progenitor cells.
We recently demonstrated that Emodin has several properties, including inhibiting leukemic cell proliferation, sensitizing resistant leukemic cells to chemotherapeutic agents and suppressing diffuse large B cell lymphoma. In this study, we increased the antileukemic properties of Emodin by designing a more pharmacologically potent derivative, E35, which retained the key features of the parent molecule. The IC50 values of E35 in 10 different leukemia/lymphoma cell lines were between 6.07-and 25.47-fold lower than those of Emodin. We then examined whether E35 may eliminate AL stem and progenitor cells. According to previous reports, KG1a cells with the similar LSC phenotype of CD34 + CD38 − are considered an ideal cell model for studying LSCs Liu et al., 2013; Weng, Zeng, Huang, Fan, & Guo, 2015) . We thus selected KG1a cells and HARs (CD34 + cells enriched from multidrug-resistant HL-60/ADR cells) to perform in vitro experiments. Our results showed that both cell proliferation and colony formation were dramatically inhibited after E35 treatment, indicating that E35 may effectively ablate LSCs.
To generate data more relevant to clinical application, primary AL cells were assessed. Peripheral blood specimens from 33 AL patients with different subtypes and seven healthy donors were collected in this study.
Interestingly, we found that E35 was able to decrease cell viability in primary AL stem and progenitor cells as well as the total blast cells. Single We further explored the underlying molecular mechanisms evoked by E35 treatment in KG1a cells. It is known that nuclear factor κB (NF-κB) modulates mesenchymal stem cell accumulation at tumors. Inhibition of NF-κB activity might contribute to apoptotic induction in LSCs (Guzman et al., 2001; Guzman et al., 2002; Guzman et al., 2014; Ji et al., 2016; Jin et al., 2017; Uchibori et al., 2013) . Mohammadi et al. (2016) reported that the Akt/mTOR/PTEN/ (Chen, Lee, Kang, Minden, & Zhang, 2018; Ding et al., 2016; Fuchs, Daniel, Sadeghi, Opelz, & Naujokat, 2010; Rao et al., 2011) .
In this study, we found that HARs and KG1a cells in response to E35 showed dramatic reductions in both mRNA and protein expression levels of MDR1, MRP1, GSTπ, TopⅡβ, and BCL-2. These molecules are associated with drug-resistance in AL (Lin et al., 2013; Wang et al., 2015) . Therefore, we speculate that blockade of the AKT/mTOR pathway and downregulation of drug-resistant genes contributes to the efficacy of E35 for LSC inhibition. The results of the cell cycle assay are concordant with those of E35-medicated growth inhibition and apoptotic induction in vitro, which also corroborate findings in several studies assessing novel therapeutic strategies for leukemia and LSCs (Chen et al., 2016; Park et al., 2018; Rahimian, Mahdavi, Rahbarghazi, & Charoudeh, 2019; Schinke et al., 2015) . However, these findings are preliminary, and it is worthwhile further investigating whether E35 may affect key cell cycle modulators, including Cyclin D1, p27, and CDK4/6. Furthermore, we evaluated the in vivo anti-leukemic activity of E35 using a human LSC-like KG1a-R xenotransplantation mouse model. All animal recipients survived at the 10th week during follow-up after initial treatment with E35. RFP signals were markedly decreased in animals administered E35. Consistently, dramatically decreased rates of humanderived CD34 + CD38 − cells in the bone marrow were observed as measured by flow cytometry, concomitant to increased amounts of differentiated myeloid cells in bone marrow smears. Taken together, we provide the preliminary evidence that E35-mediated anti-LSC activity can occur in the xenograft model. It has been reported that different events jointly inhibit LSCs in vivo. For example, Ding et al. (2016) showed that alantolactone dose-dependently induces apoptosis in KG1a cells via suppression of NF-κB and its downstream target proteins, while its prodrug DMA-alantolactone could greatly inhibit KG1a xenograft in vivo. Guzman et al. (2007) found that the anti-LSC activity mediated by (a) (b) (c) F I G U R E 6 In vivo therapeutic effects of E35 in KG1a-R xenograft mice. Nude mice harboring KG1a-R xenografts were randomized into two groups and intraperitoneally administered 20 mg/kg E35 or vehicle once daily for 2 weeks. All animals were followed up for 10 weeks after the initial treatment with E35. (a)The leukemic burden was assessed on an IVIS LUMINA II Imaging System. (b) Harvested bone marrow (BM) cells were stained by the Wright-Giemsa method.
(c) The percentages of CD34 + CD38 − KG1a-R cells in BM were measured by flow cytometry. ****p < .0001 versus vehicle control the dimethyl-amino analog of parthenolide in canine models is strongly associated with induced oxidative stress responses and NF-κB suppression. The latter authors also reported that Histone Deacetylase Inhibitor AR-42 reduces Hsp90's ability to stabilize its oncogenic effectors, causing enhanced and specific cytotoxicity in LSCs (Guzman et al., 2014) . Our findings demonstrated that the therapeutic response to E35 is mediated, at least in part, by differentiation induction in LSCs.
However, the underpinning molecular mechanisms still need to be explored under in vitro and in vivo settings.
In summary, we identified E35 as a novel agent that can ablate AL cells at the bulk, stem, and progenitor cell levels. Going forward, further investigation in large animal models may enable greater success in applying this compound to clinical cases.
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